News & Insights

This is where we share our own and our portfolio companies’ press releases as well as relevant Sunstone articles, analyses and SoMe posts.

5 latest news

Ascelia Pharma Successfully Meets Primary Endpoint with Strong Headline Results in Orviglance Phase 3 Study

Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that liver imaging drug candidate, Orviglance®, significantly improved visualization of focal liver lesions, successfully...

Fund IV company Cardior Pharmaceuticals acquired by Novo Nordisk

Cardior is a leader in the discovery and development of therapies that target RNA as a means to prevent, repair and reverse diseases of the heart. The company’s therapeutic approach targets distinctive non-coding RNAs as a platform for addressing root causes of...

A Sunstone team update

After 17 years as General Partner and co-founder of Sunstone Life Science Ventures and almost 40 years in the life science industry, our colleague Sten Verland will be taking on a part-time role as Venture Partner as of February 1. Sten will continue to manage his...

Sunstone Life Science Ventures divests its holding in Arcoma AB

Sunstone announces that one hundred percent of the holding in Arcoma AB have been sold in a structured block sale. Sunstone has been a major owner in Arcoma since 2010 and is proud of what the company has achieved in delivering world-class digital radiographic...

Sunstone Life Science Ventures joins EUR 57 Million Series A Investment in Kynexis to Advance Development of Novel Therapeutics for Cognitive Disorders

Sunstone Life Science Ventures (Sunstone), a leading Nordic venture capital firm, is excited to announce its participation in a EUR 57 million Series A funding round for Kynexis B.V., a pioneering biotech company dedicated to advancing treatments for cognitive...

The VC summer dream – the Fund Returner

Sunstone has over the past years continuously highlighted observations and learnings from successes in European biotech. The learnings have consolidated, tuned and verified our current investment strategy. Sunstone is today primarily an early stage (pre-clinical/phase...

Are we making a tangible difference?

We are a Life Science Venture Capital with a passion for investing in drug development, both because it is extremely exciting but also because we contribute to moving new therapies closer to patients with severe, untreated diseases – we matter! – we make a tangible...

Sunstone has supported and funded companies that have been the originator of 20 life-changing products

Since the inception in 2007, Sunstone Life Science Ventures (Sunstone) has co-created, supported and funded life science companies that have been the originator of 20 life-changing products approved for the treatment or diagnosis of patients with cardiovascular,...

Biotech startups in Scandinavia have 460 MEUR at hand – but burn is up – and runway the shortest in 3 years

As the market continues to fluctuate and geopolitical issues continue to impact the economy, it's important to take a closer look at the state of pre-commercial life science companies. At Sunstone, we assisted companies in our portfolio with listings and refinancing,...

Unmet medical needs in cardiovascular sub-populations – an opportunity for VCs?

Unmet medical needs in cardiovascular sub-populations – an opportunity for VCs? For the past 5 months we have had the pleasure of having Philip Brainin as intern at Sunstone Life Science Ventures. Apart from bringing valuable insights to our daily activities, he has...

Why do VC’s not cut losses in time?

Why do VC’s not cut losses in time? A clinical trial is a very expensive experiment for testing a hypothesis, while hoping for a positive outcome. However, if well designed, a negative outcome could increase the potential for a positive outcome in a subsequent trial....

Ascelia Pharma’s new share issue in connection with the IPO on Nasdaq Stockholm was significantly oversubscribed

by Sunstone Life Science Ventures | Mar 7, 2019

The offering in Ascelia Pharma AB (“Ascelia Pharma” or the “Company”) in connection with the Initial Public Offering on Nasdaq Stockholm was significantly oversubscribed. The new share issue (the “Offering”) will provide Ascelia Pharma with approximately SEK 200...

Arcoma: Omsättningen ökar 36%: fortsatta resultatförbättringar:

by Sunstone Life Science Ventures | Feb 22, 2019

Arcomas kvartalsrapport för fjärde kvartalet 2018 – bokslutskommuniké – finns att läsa här Press inquiries should be adressed to:   

Ascelia Pharma publishes prospectus in connection with Initial Public Offering on Nasdaq Stockholm

by Sunstone Life Science Ventures | Feb 21, 2019

Ascelia Pharma AB (“Ascelia Pharma” or the “Company”) has decided to issue new shares to the general public in Sweden and Denmark as well as institutional investors in Sweden and abroad (the “Offering”). The Company’s Board of Directors also intend to apply for...

Sunstone announce new corporate structure and brand names

by Sunstone Life Science Ventures | Feb 14, 2019

Sunstone Capital today announce that the two investment arms of Sunstone – Life Science Ventures and Technology Ventures – in the future will operate under the names Sunstone Life Science Ventures ( https://sunstone.eu ) and Heartcore Capital, respectively....

Sunstone Life Science Ventures Fund IV announces first close

by Sunstone Life Science Ventures | Feb 7, 2019

Sunstone Life Science Ventures today announced the first closing of its Sunstone Life Science Ventures Fund IV (“Sunstone LSV IV”) at €80 million. The investment strategy of the new fund is a continuation of Sunstone’s successful strategy of investing in novel...

Insights Archive

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.